Paris (France), June 19, 2020 – 5.45 pm CEST - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, announces that the Extraordinary General Meeting held today in camera on second call was able to validly deliberate The quorum was largely achieved, with 30.92% of the voting rights represented.

Onxeo's shareholders voted all the resolutions presented in accordance with the recommendations of the Board of Directors.

The company would like to thank all of its shareholders for their commitment and support.

The minutes of the meeting will be available within the statutory deadlines on Onxeo's website, in the General Meetings section.

• Access the press release in .pdf format